Avidity Biosciences, Inc. Stock Price, News & Analysis

Avidity Biosciences (Nasdaq: RNA) has received FDA Fast Track designation for its RNA therapeutic, AOC 1044, intended for treating Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping (DMD44). This designation promotes expedited development and review processes due to the serious nature of DMD, which lacks approved therapies targeting exon 44. AOC 1044 is currently in a Phase 1/2 clinical trial, EXPLORE44™, which aims to evaluate its safety and efficacy. The trial will involve around 64 participants, including healthy volunteers and DMD patients, and results are expected in late 2023. Avidity emphasizes its ongoing commitment to deliver effective treatments for rare diseases, as AOC 1044 is one of several AOCs in development for DMD.

Avidity Biosciences, Inc. (NASDAQ: RNA) announced on April 20, 2023, that its Human Capital Management Committee granted stock options and restricted stock units (RSUs) to 12 new non-executive employees. Specifically, 58,300 stock options and 29,150 RSUs were awarded under the 2022 Employment Inducement Incentive Award Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $15.75, equal to the closing stock price on the grant date. The options will vest over four years, while the RSUs will vest in four equal installments over four years. Avidity focuses on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), with ongoing clinical trials for several conditions, including myotonic dystrophy and Duchenne muscular dystrophy.

Avidity Biosciences, Inc. (Nasdaq: RNA) announced its upcoming presentations at the 75th American Academy of Neurology (AAN) Annual Meeting occurring in Boston from April 22-27, 2023. Key highlights include an oral presentation on April 27, focusing on the AOC 1001 Phase 1/2 MARINA™ trial, which evaluates the safety, biomarker, and functional data for patients with Myotonic Dystrophy Type 1 (DM1). Additionally, a poster presentation on April 23 will cover the AOC 1020 trial design for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). Avidity's commitment is to advance its RNA therapeutics, specifically Antibody Oligonucleotide Conjugates (AOCs™), targeting diseases previously considered untreatable. For more information, visit Avidity's website.

Avidity Biosciences (Nasdaq: RNA) announced an investor and analyst event on April 27, 2023, in Boston, showcasing topline safety, biomarker, and functional data from the AOC 1001 Phase 1/2 MARINA trial for myotonic dystrophy type 1 (DM1). The event, starting at 5:30 p.m. ET, will be accessible via webcast. Lead investigator Nicholas E. Johnson will present this data earlier that day at the 75th American Academy of Neurology Annual Meeting. Avidity’s AOC 1001 aims to address DM1, part of a growing pipeline of innovative RNA therapeutics, which also includes treatments for facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy. The company continues to advance its mission to deliver targeted therapies to previously untreatable diseases.

Avidity Biosciences (RNA) has provided an update on its AOC 1001 treatment for myotonic dystrophy type 1 (DM1) from the Phase 1/2 MARINA trial. The FDA continues discussions regarding a partial clinical hold initiated in September 2022 due to a serious adverse event in a single participant. Avidity has found no biological link between the event and AOC 1001. Preliminary results show successful RNA delivery and early signs of clinical activity. A top-line safety data presentation is scheduled for the AAN Annual Meeting on April 27, 2023. Further dosing will occur in the ongoing MARINA-OLE extension study, with expectations for 2023 data release.

Avidity Biosciences, Inc. (Nasdaq: RNA) announced the granting of non-qualified stock options for 73,700 shares and 36,850 restricted stock units (RSUs) to six new non-executive employees on March 20, 2023. This is part of the company's 2022 Employment Inducement Incentive Award Plan, aimed at attracting talent following Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $20.07 per share, equal to the closing price on the grant date, and will vest over four years. Avidity is focused on developing Antibody Oligonucleotide Conjugates (AOCs™) to target diseases previously untreatable by RNA therapeutics.

Avidity Biosciences (Nasdaq: RNA) announced its participation in the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, from March 19-22, 2023. The company will present two oral presentations on March 22, focusing on AOC 1020 for FSHD and the MARINA™ Trial for Myotonic Dystrophy Type 1. Additionally, Avidity will showcase multiple poster presentations covering various topics including healthcare utilization in Myotonic Dystrophy and innovative therapies for Duchenne Muscular Dystrophy. Presentations will be available on Avidity's website after the event.

Avidity Biosciences, Inc. (Nasdaq: RNA) announced its participation in the Cowen 43rd Annual Healthcare Conference on March 7 at 8:10 a.m. PT / 11:10 a.m. ET. A live webcast will be available on the 'Events and Presentations' page of Avidity's website, providing up-to-date details and an archived replay. Avidity is focused on developing a new class of RNA therapeutics, known as Antibody Oligonucleotide Conjugates (AOCs™), and currently has three programs in clinical development targeting various muscular dystrophies. The company aims to address previously untreatable diseases through its innovative therapies.